Medikit Co.,Ltd.
Stock Price Chart
2026/08/21 UpdatedPrice Trend
2026/08/21 UpdatedPrice & Trading Details
2026/08/21 UpdatedPRICE
TRADING
Shareholder Composition
Updated 2026/08/01Dividend History
Updated 2026/08/23| Year | Dividend | Change |
|---|---|---|
| 2026 | ¥50 | -47.4% |
| 2025 | ¥95 | +5.6% |
| 2024 | ¥90 | -14.3% |
| 2023 | ¥105 | +16.7% |
| 2022 | ¥90 | - |
Financial Performance
2026/08/23 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | ¥21,607M | ¥21,851M | ¥22,553M | ¥23,781M |
| Gross Profit | ¥8,319M | ¥8,753M | ¥8,668M | ¥9,008M |
| Operating Income | ¥4,118M | ¥4,678M | ¥4,487M | ¥4,272M |
| Pretax Income | ¥4,299M | ¥4,783M | ¥4,667M | ¥4,520M |
| Net Income | ¥2,865M | ¥3,069M | ¥3,014M | ¥3,006M |
| EPS | ¥170.67 | ¥187.95 | ¥204.55 | ¥206.37 |
| Operating Margin | 19.06% | 21.41% | 19.89% | 17.97% |
| Balance Sheet | ||||
| Total Assets | ¥53,186M | ¥50,999M | ¥52,471M | ¥53,272M |
| Total Equity | ¥47,292M | ¥44,129M | ¥45,156M | ¥46,781M |
| Total Liabilities | ¥5,894M | ¥6,871M | ¥7,315M | ¥6,491M |
| Cash | ¥27,593M | ¥23,611M | ¥21,559M | ¥20,953M |
| Interest-bearing Debt | - | - | ¥0M | ¥19M |
| Equity Ratio | 88.92% | 86.53% | 86.06% | 87.82% |
| D/E Ratio | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow | ||||
| Operating CF | ¥4,480M | ¥4,834M | ¥3,562M | ¥4,735M |
| Investing CF | -¥3,582M | ¥3,231M | -¥3,871M | -¥1,293M |
| Financing CF | -¥1,510M | -¥6,584M | -¥1,879M | -¥1,821M |
| Free CF | ¥3,455M | ¥3,128M | -¥288M | ¥1,252M |
| Efficiency | ||||
| ROE | 6.06% | 6.96% | 6.67% | 6.43% |
| ROA | 5.39% | 6.02% | 5.74% | 5.64% |
Latest IR Information
-
【Medikit】Completion of Share Buyback of Restricted Shares｜July 2026
Medikit announced that it disposed of 12,700 shares of treasury stock on July 24, 2026, raising a total of 35,394,900 yen.
Read more -
Notice of Share Acquisition of T.G. Medical by July 3, 2026
Resolution to consolidate into a consolidated subsidiary to expand sales. Togo Medikit acquires all shares of T.G. Medical and its stock acquisition rights, becoming a wholly owned subsidiary. Shares acquired: 2,211 shares and 331 stock acquisition rights, ownership ratio: 100.0%....
Read more -
[Medikit] Share Buyback and Incentive Program Introduction | July 2026
Medikit plans to dispose of 12,700 shares of treasury stock on July 24, 2026, raising a total of 35.39 million yen. This is part of an incentive program for directors and officers.
Read more -
Fiscal Year Ending March 2026 Q3 Financial Summary [Japanese GAAP] (Consolidated)
For the nine-month period ended December 31, 2025, net sales were 184.666 billion yen (6.5% increase YoY), operating income was 3.657 billion yen (0.8% increase YoY), and net income attributable to owners of parent was 2.236 billion yen (3.8% increase...
Read more
Latest News (5 items)
Company Information
About
Medikit Co.,Ltd., together with its subsidiaries, develops, manufactures, and sells medical devices related to blood vessels and blood in Japan and internationally. The company offers IV catheters, such as Supercath 5 and Supercath Ztu-V; hemodialysis products, including Supercath PRO, Supercath NEO, and Supercath Clampcath; and intervention products comprising Supersheath sheath introducers and Mongoose angiography catheters. It also provides indwelling needles for artificial dialysis; and needles for blood transfusions and intravenous fluid. Medikit Co.,Ltd. was founded in 1973 and is headquartered in Bunkyo, Japan.
